Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Valproic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.94 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.94 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.94 |
| ▸ | HTR2A | P28223 | 1/20 | 0.94 |
| ▸ | HTR2C | P28335 | 1/20 | 0.94 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.94 |
| ▸ | HRH1 | P35367 | 1/20 | 0.94 |
| ▸ | DRD3 | P35462 | 1/20 | 0.94 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.94 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.94 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.94 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.94 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.60 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.60 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.60 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.60 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valproic Acid SCHEMBL2054191 | 1.00 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL6910916 | 1.00 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL1685069 | 1.00 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL7579608 | 1.00 | CHRM1 (0.94) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL27925984 | 0.97 | CHRM1 (0.89) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL28857465 | 0.97 | CHRM1 (0.89) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL2275 | 0.97 | CHRM1 (1.00) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL1330837 | 0.97 | CHRM1 (1.00) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL140241 | 0.97 | CHRM1 (1.00) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL28895465 | 0.95 | CHRM1 (0.84) | CHRM1AKR1A1CHRM3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 709 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115154424-B | Low-hygroscopicity solid dispersion containing sodium valproate, preparation method thereof and sustained-release tablet core | 广州茂丰药业有限公司 | 2024-06-21 | — | — | CN | claimed |
| US-11844862-B2 | Treatment of ocular conditions utilizing a histone/protein deacetylase inhibitor | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-12-19 | — | — | US | claimed |
| US-20230159888-A1 | MEDIUM-BASED METHOD REALIZED FOR DIFFERENTIATION OF DENTAL STEM CELLS INTO NEURONS | YEDITEPE UNIVERSITESI (TR) | 2023-05-25 | — | — | US | claimed |
| EP-4146791-A1 | A MEDIUM-BASED METHOD REALIZED FOR DIFFERENTIATION OF DENTAL STEM CELLS INTO NEURONS | Yeditepe Universitesi (TR) | 2023-03-15 | — | — | EP | claimed |
| CN-115154424-A | Low-hygroscopicity solid dispersion containing sodium valproate, preparation method of low-hygroscopicity solid dispersion and sustained-release tablet core | 广州茂丰药业有限公司 | 2022-10-11 | — | — | CN | claimed |
| CN-114875107-A | POLR2A as biomarker for treating tumor curative effect | 中南大学 | 2022-08-09 | — | — | CN | claimed |
| CN-108865972-B | Cell culture solution | 布里格海姆妇女医院公司 | 2022-07-29 | — | — | CN | claimed |
| US-20220125729-A1 | TREATMENT OF OCULAR CONDITIONS UTILIZING A HISTONE/PROTEIN DEACETYLASE INHIBITOR | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-04-28 | — | — | US | claimed |
| US-11253480-B2 | Treatment of ocular conditions utilizing a histone/protein deacetylase inhibitor | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2022-02-22 | — | — | US | claimed |
| US-20220008365-A1 | Treating Intraocular Retinoblastoma with Inhibitors of Histone Modification | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-13 | — | — | US | claimed |
| CN-108992396-A | A kind of preparation method of Sodium Valproate | 刘丽 | 2018-12-14 | — | — | CN | claimed |
| WO-2018206798-A1 | SYSTEMS | PARMAR MALIN (SE) | 2018-11-15 | — | — | WO | claimed |
| CN-108300686-A | For preventing, delaying or micromolecular compound/combination of reverse both, tissue, organ, body aging, product and application thereof | 云南美颜美龄生物科技有限公司 | 2018-07-20 | — | — | CN | claimed |
| US-20170252449-A1 | SOLUBILIZED COMPOSITIONS FOR CONTROLLED PROLIFERATION OF STEM CELLS / GENERATING INNER EAR HAIR CELLS USING GSK3 INHIBITORS: III | Frequency Therapeutics, Inc. | 2017-09-07 | — | — | US | claimed |
| US-20150344874-A1 | Screening method for drug target gene using heterozygous deletion fission yeast strain | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2015-12-03 | — | — | US | claimed |
| CN-101453993-A | Controlled release delivery device containing organosol coating | ISA ODIDI (CA) | 2009-06-10 | — | — | CN | claimed |
| WO-2005049039-A1 | COMBINATIONS COMPRISING AMPA RECEPTORS ANTAGONISTS FOR THE TREATMENT OF AFFECTIVE AND ATTENTION DEFICIT DISORDERS | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | claimed |
| EP-1328261-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | Minerva Biotechnologies Corporation (US) | 2003-07-23 | — | — | EP | claimed |
| US-20030060487-A1 | Treatment of neurodegenerative disease | MINERVA BIOTECHNOLOGIES CORPORATION | 2003-03-27 | — | — | US | claimed |
| WO-2001078709-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2001-10-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060487-A1 | Treatment of neurodegenerative disease | HTT, IAPP, APP | CHRM1 3695/4885AKR1A1 4388/4885CHRM3 2621/4885 |
| US-20220008365-A1 | Treating Intraocular Retinoblastoma with Inhibitors of Histone Modification | RB1, HDAC1, HDAC9 | CHRM1 4656/4885AKR1A1 2878/4885CHRM3 4358/4885 |
| US-20170252449-A1 | SOLUBILIZED COMPOSITIONS FOR CONTROLLED PROLIFERATION OF STEM CELLS / GENERATING INNER EAR HAIR CELLS USING GSK3 INHIBITORS: III | GSK3B, GSK3A, GSKIP | CHRM1 4850/4885AKR1A1 2511/4885CHRM3 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.